RC
CABA icon

Rangeley Capital’s Cabaletta Bio CABA Stock Holding History

Rangeley Capital’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,300
Closed -$26.4K – 129
2025
Q3 		$26.4K Sell
11,300
-4,700
-29% -$8.06K 0.02% 124
2025
Q2 		$24.3K Buy
+16,000
New +$25K 0.03% 69

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rangeley Capital's CABA Position: Q4 2025 in Review

Rangeley Capital sold out of Cabaletta Bio (CABA) in Q4 2025, closing a stake of 11,300 shares — an estimated $26.4K sold.

Rangeley Capital first reported a position in CABA in Q2 2025 and held it in 2 quarters. The position peaked at $26.4K in Q3 2025. 95 funds tracked by Wall St. Rank hold CABA as of Q4 2025.

  • Rangeley Capital reported no remaining Cabaletta Bio position as of Q4 2025 after selling out during the quarter.
  • Rangeley Capital sold 11,300 Cabaletta Bio shares in Q4 2025, an estimated $26.4K.
  • Rangeley Capital first reported a position in Cabaletta Bio in Q2 2025 and held it in 2 quarters.
  • Rangeley Capital's Cabaletta Bio position peaked at $26.4K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2025.

Based on Rangeley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.